Skip to main content
      Day 2 Report - ACR Plenaries: Changing the Practice of Rheumatology

      The top ACR2023 Plenary abstracts Dr. Dao ( @kdao2

      Dr. John Cush RheumNow

      1 year 6 months ago
      Day 2 Report - ACR Plenaries: Changing the Practice of Rheumatology The top ACR2023 Plenary abstracts Dr. Dao ( @kdao2011) found impactful for her practice were... https://t.co/aXut7l7b79 https://t.co/ATO5r5OzGK
      Chronic low back pain is a common complaint that brings patients to the doctor’s attention. Although the majority of low back pain is mechanical in nature, an important minority is inflammatory in nature. Therefore, prompt referral to a rheumatologist is warranted particularly in the presence of other features suggestive of axial spondyloarthritis (axSpA).
      Rheumatology Roundup
      Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.
      ACR23 – Day 3 Report

      F2F learning amidst miles of research and many young talented aside wizened establish presente

      Dr. John Cush RheumNow

      1 year 6 months ago
      ACR23 – Day 3 Report F2F learning amidst miles of research and many young talented aside wizened establish presenters is such a welcome return to ACR, the way it should be. https://t.co/TwmwfEQZdp https://t.co/Yo27c7ig8N
      Watch: Lupus Nephritis Therapy Paradigm Shift

      Dr. Yuz Yusof reporting on abstract 0782 at the 2023 ACR Convergence mee

      Dr. John Cush RheumNow

      1 year 6 months ago
      Watch: Lupus Nephritis Therapy Paradigm Shift Dr. Yuz Yusof reporting on abstract 0782 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/poIVX74EnO https://t.co/tWlRlwTfH0
      IV Secukinumab for AxSpa

      The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with ps

      Dr. John Cush RheumNow

      1 year 6 months ago
      IV Secukinumab for AxSpa The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis. https://t.co/eDAWevPLkE https://t.co/AlWYGAQP5T
      Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA

      Dr. Robert Chao (Tysons, VA) discusses Abst

      Dr. John Cush RheumNow

      1 year 6 months ago
      Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA Dr. Robert Chao (Tysons, VA) discusses Abstract 0522 presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/UmcbplfGhB https://t.co/R5Lr6Q0qHI
      How early is early in psoriatic arthritis?

      Is there a window of opportunity for treatment in PsA to ensure optimal ou

      Dr. John Cush RheumNow

      1 year 6 months ago
      How early is early in psoriatic arthritis? Is there a window of opportunity for treatment in PsA to ensure optimal outcomes? https://t.co/SHA8Gdm1GD https://t.co/GbFfeB2Euw
      Cancer and TNF inhibitors

      Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for

      Dr. John Cush RheumNow

      1 year 6 months ago
      Cancer and TNF inhibitors Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions https://t.co/MzksmSEUjf https://t.co/dxCIHxL1gc
      ×